ShareCompartir
Volume 24, Number 1—January 2018
Research
Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia
Alex Y.C. Tai
, Eugene Athan, N. Deborah Friedman, Andrew Hughes, Aaron Walton, and Daniel P. O’Brien
, Eugene Athan, N. Deborah Friedman, Andrew Hughes, Aaron Walton, and Daniel P. O’Brien
Table 2
Logistic regression analysis of adjusted and unadjusted associations between patient characteristics and severe Mycobacterium ulcerans disease, Barwon Health Cohort, Geelong, Victoria, Australia, January 1998–May 2017*
| Characteristic | Nonsevere disease, no. (%) | Severe disease, no. (%) | Crude odds ratio (95% CI) | p value | Adjusted odds ratio (95% CI) | p value |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| ≤15 | 31 (77.5) | 9 (22.5) | 1.62 (0.71–3.71) | 0. 004 | 1.73 (0.73–4.12) | 0.006 |
| 16–64 | 184 (84.8) | 33 (15.2) | 1 | 1 | ||
| ≥65 |
120 (71.0) |
49 (29.0) |
2.28 (1.38–3.75) |
2.34 (1.38–3.98) |
||
| Sex | ||||||
| F | 156 (79.6) | 40 (20.4) | 1 | 0.66 | 1 | 0.51 |
| M |
179 (77.8) |
51 (22.2) |
1.11 (0.70–1.77 |
1.18 (0.72–1.94) |
||
| Location | ||||||
| Mornington Peninsula | 72 (70.6) | 30 (29.4) | 1 | 0.03 | 1 | 0.24 |
| Bellarine Peninsula |
263 (81.2) |
61 (18.8) |
0.56 (0.33–0.93) |
0.71 (0.40–1.26) |
||
| Lesion over a joint | ||||||
| No | 228 (84.4) | 42 (15.6) | 1 | <0.001 | 1 | <0.001 |
| Yes |
107 (68.6) |
49 (31.4) |
2.67 (1.64–4.36) |
2.71 (1.65–4.43) |
||
| Time period | ||||||
| 1998–2004 | 29 (85.3) | 5 (14.7) | 1 | 0.01 | 1 | 0.03 |
| 2005–2010 | 85 (87.6) | 12 (12.4) | 0.82 (0.27–2.52) | 0.88 (0.28–2.80) | ||
| 2011–2017 |
221 (74.9) |
74 (25.1) |
1.94 (0.73–5.20) |
2.11 (0.74–5.99) |
||
| Duration of symptoms before diagnosis, d | ||||||
| ≤75 | 241 (77.7) | 69 (22.3) | 1 | 0.76 | NA | NA |
| >75 | 81 (81.0) | 19 (19.0) | 0.82 (0.46–1.44) | |||
| Missing |
13 (81.3) |
3(18.8) |
0.81 (0.22–2.91) |
|||
| Diabetes mellitus | ||||||
| No | 312 (79.8) | 79 (20.2) | 1 | 0.06 | 1 | 0.14 |
| Yes |
23 (65.7) |
12 (34.3) |
2.06 (0.98–4.32) |
1.86 (0.82–4.23) |
||
| Immune suppression | ||||||
| No | 310 (79.3) | 81 (20.7) | 1 | 0.31 | NA | NA |
| Yes | 25 (71.4) | 10 (28.6) | 1.50 (0.69–3.27) | |||
*Adjusted for age, sex, location, position of lesion over a joint, time period, and diabetes mellitus. NA, not applicable.
- Page created: December 19, 2017
- Page last updated: December 19, 2017
- Page last reviewed: December 19, 2017
- Centers for Disease Control and Prevention,
-
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)